PriceTargets.com logo

NeuroBo Pharmaceuticals - NRBO Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.10 As of 04/24/2024 01:00 AM ET
▲ +0.08 (2.65%)

This chart shows the closing price for NRBO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NeuroBo Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NRBO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NRBO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for NeuroBo Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.10.

This chart shows the closing price for NRBO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in NeuroBo Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/7/2022LADENBURG THALM/SH SHInitiated CoverageBuyLow
8/31/2021HC WainwrightReiterated RatingBuy$3,840.00High
4/20/2021HC WainwrightReiterated RatingBuy$3,840.00High
2/1/2021HC WainwrightLower TargetBuy$4,800.00 ➝ $3,840.00Low
11/16/2020HC WainwrightReiterated RatingBuy$4,800.00High
6/15/2020HC WainwrightInitiated CoverageBuy$4,800.00High
2/18/2020LADENBURG THALM/SH SHInitiated CoverageBuyHigh
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

NeuroBo Pharmaceuticals logo
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $3.10
Low: $2.99
High: $3.50

50 Day Range

MA: $4.51
Low: $3.02
High: $6.52

52 Week Range

Now: $3.10
Low: $2.89
High: $6.75

Volume

39,253 shs

Average Volume

1,065,755 shs

Market Capitalization

$15.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of NeuroBo Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on NeuroBo Pharmaceuticals in the last year:
View the latest analyst ratings for NRBO.

What is the current price target for NeuroBo Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for NeuroBo Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for NeuroBo Pharmaceuticals in the next year.
View the latest price targets for NRBO.

What is the current consensus analyst rating for NeuroBo Pharmaceuticals?

NeuroBo Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NRBO.

What other companies compete with NeuroBo Pharmaceuticals?

Other companies that are similar to NeuroBo Pharmaceuticals include Aytu BioPharma, Kiora Pharmaceuticals, Edesa Biotech, ABVC BioPharma and Traws Pharma. Learn More about companies similar to NeuroBo Pharmaceuticals.

How do I contact NeuroBo Pharmaceuticals' investor relations team?

NeuroBo Pharmaceuticals' physical mailing address is 200 Berkeley Street Office 19th Floor, Boston MA, 02116. The company's listed phone number is (857) 702-9600 and its investor relations email address is [email protected]. The official website for NeuroBo Pharmaceuticals is www.neurobopharma.com. Learn More about contacing NeuroBo Pharmaceuticals investor relations.